| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VTI1B |
| Uniprot No | Q9UEU0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-208aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMASSAAS SEHFEKLHEI FRGLHEDLQG VPERLLGTAG TEEKKKLIRD FDEKQQEANE TLAEMEEELR YAPLSFRNPM MSKLRNYRKD LAKLHREVRS TPLTATPGGR GDMKYGIYAV ENEHMNRLQS QRAMLLQGTE SLNRATQSIE RSHRIATETD QIGSEIIEEL GEQRDQLERT KSRLVNTSEN LSKSRKILRS MSRKVTTNKL L |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VTI1B重组蛋白的3篇示例参考文献(注：以下内容为模拟生成，实际文献需通过学术数据库查询确认)：
---
1. **文献名称**：Structural and Functional Characterization of VTI1B in Intracellular Vesicle Trafficking
**作者**：Kuster, J., et al.
**摘要**：本研究通过重组表达并纯化人源VTI1B蛋白，结合X射线晶体学解析其三维结构，揭示了其与SNARE复合体相互作用的分子机制，证实其在胞内运输囊泡膜融合中的关键作用。
2. **文献名称**：VTI1B Recombinant Protein Facilitates Neurosecretory Vesicle Docking in Neurons
**作者**：Wang, L., & Zhang, Y.
**摘要**：利用重组VTI1B蛋白进行体外囊泡结合实验，发现其通过与Syntaxin蛋白家族的特异性结合，调控神经递质囊泡的锚定过程，为神经退行性疾病研究提供新靶点。
3. **文献名称**：Development of a High-Throughput Screening Assay Using Recombinant VTI1B for Drug Discovery
**作者**：Smith, R., et al.
**摘要**：报道了一种基于重组VTI1B蛋白的药物筛选平台，通过检测小分子化合物对VTI1B与伴侣蛋白结合的干扰效应，筛选潜在治疗囊泡运输障碍疾病的候选药物。
---
**说明**：以上为模拟文献，实际研究中建议通过PubMed、Web of Science等平台，以“VTI1B recombinant protein”、“VTI1B vesicle trafficking”等关键词检索最新研究。若文献较少，可扩展至VTI1B的同源蛋白(如VTI1A)或相关通路(如SNARE复合体)的研究。
VTI1B (Vesicle Transport through Interaction with t-SNAREs homolog 1B) is a SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor) family protein involved in intracellular vesicle trafficking, a critical process for maintaining cellular homeostasis, signal transduction, and organelle communication. It plays a specialized role in mediating membrane fusion events between transport vesicles and target membranes, particularly in late endosomal, lysosomal, and trans-Golgi network pathways. Structurally, VTI1B contains a conserved SNARE domain that enables it to form specific helical bundles with partner SNAREs (e.g., syntaxins and SNAP proteins), driving the docking and fusion of vesicles.
Recombinant VTI1B protein is engineered for in vitro studies to dissect its molecular interactions, regulatory mechanisms, and functional roles in vesicular transport. Produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), the recombinant protein retains key functional epitopes while enabling high-purity isolation through affinity tags (e.g., His-tag or GST-tag). This tool has been instrumental in elucidating VTI1B's participation in autophagy, neurotransmitter release, and immune response pathways. Dysregulation of VTI1B has been implicated in neurodegenerative diseases (e.g., Alzheimer’s) and cancer metastasis, making its recombinant form valuable for drug screening and mechanistic studies. Recent research also highlights its interaction with pathogens, suggesting roles in intracellular pathogen survival. Optimized recombinant VTI1B variants (e.g., mutation studies) further aid in mapping binding interfaces and post-translational modification effects, bridging structural biology with cellular pathophysiology.
×
